Niacin And NAD+: Vitamin B3

Niacin

Niacin is vitamin B3, one of the eight B vitamins and a water-soluble nutrient that the body converts into nicotinamide adenine dinucleotide (NAD+), one of the most important coenzymes in human biochemistry. NAD+ participates in over 400 enzymatic reactions, including the core pathways of energy metabolism, DNA repair, and cellular signaling. Its centrality to metabolism is difficult to overstate: without NAD+, cells cannot extract energy from food or repair damaged DNA, and the epigenetic machinery that controls gene expression stops functioning.

Niacin has also had one of the more dramatic arcs in supplement and pharmaceutical history. It was the cure for pellagra, a devastating deficiency disease. It became a first-line drug for cholesterol management. Then two large trials showed it didn’t reduce cardiovascular events when added to statin therapy, and its use for that purpose collapsed. More recently, interest has shifted to NAD+ precursors like nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), which are marketed as longevity supplements based on the observation that NAD+ levels decline with age.

This article covers the biochemistry of niacin and NAD+, the different forms available as supplements, what happened to the cholesterol story, and where the evidence currently stands for NAD+ precursor supplementation.

A necessary disclaimer: If you have been diagnosed with a lipid disorder, liver disease, diabetes, or gout, work with a qualified medical professional. Pharmacological doses of niacin have significant side effects and drug interactions. This article is educational. It is not a treatment plan, a diagnostic tool, or a substitute for clinical care.

NAD+ and what it actually does

NAD+ exists in two forms: the oxidized form (NAD+) and the reduced form (NADH). The interconversion between these two forms is what makes NAD+ useful. In catabolic reactions (breaking down food for energy), NAD+ accepts electrons from glucose and fatty acid oxidation, becoming NADH. NADH then donates those electrons to the mitochondrial electron transport chain, generating ATP. The phosphorylated version, NADP+/NADPH, serves a parallel role in anabolic reactions, providing the reducing power for biosynthesis of fatty acids, cholesterol, and other molecules.

But NAD+ does far more than shuttle electrons. It is a consumed substrate for several enzyme families that play roles in cellular maintenance and signaling:

Sirtuins are NAD+-dependent deacetylases that remove acetyl groups from proteins, including histones. This activity regulates gene expression, mitochondrial function, inflammation, and stress resistance. Sirtuins have been heavily studied in the context of aging because their activity depends on NAD+ availability, and NAD+ levels decline with age. The connection between NAD+, sirtuins, and longevity is the primary driver of interest in NAD+ precursor supplements.¹

Poly(ADP-ribose) polymerases (PARPs) consume NAD+ to build ADP-ribose polymers on damaged DNA, flagging it for repair. PARP activity is critical for genomic stability, but heavy PARP activation during severe DNA damage can deplete cellular NAD+ pools, creating an energy crisis.

CD38 is an NAD+-consuming enzyme whose activity increases with age and chronic inflammation. Rising CD38 activity is thought to be one of the major contributors to age-related NAD+ decline, potentially even more significant than reduced NAD+ synthesis.²

This dual role of NAD+ as both an energy metabolism coenzyme and a substrate for signaling enzymes is what makes it relevant to aging research. The decline in NAD+ with age is more than an incidental biomarker. It simultaneously reduces energy production capacity, impairs DNA repair, and diminishes sirtuin-mediated cellular maintenance.

The forms of vitamin B3

The consumer confusion around niacin starts with the number of forms available, each with different pharmacological profiles.

Nicotinic acid (NA) is the original niacin. It is effective at raising HDL cholesterol and lowering LDL and triglycerides at pharmacological doses (1,000-3,000 mg/day). It is also the form that causes flushing, the uncomfortable skin reddening and warmth that occurs when nicotinic acid activates the GPR109A receptor in the skin, triggering prostaglandin D2 release. The flush is harmless but unpleasant enough that it was a major barrier to patient compliance and prompted the development of flush-free alternatives. Nicotinic acid enters NAD+ synthesis through the Preiss-Handler pathway.³

Nicotinamide (NAM), also called niacinamide, is the amide form of niacin. It does not cause flushing and is the preferred form for treating niacin deficiency. It enters NAD+ synthesis through the salvage pathway. The important caveat is that nicotinamide inhibits sirtuins at high concentrations, because nicotinamide is a product of sirtuin reactions and acts as feedback inhibition. This means that high-dose nicotinamide supplementation could theoretically reduce the very sirtuin activity that NAD+ is supposed to support.⁴

Nicotinamide riboside (NR) is a more recently characterized NAD+ precursor that enters the salvage pathway through nicotinamide riboside kinases (NRK1/2), bypassing the rate-limiting NAMPT enzyme that nicotinamide must pass through. This gives NR a theoretical efficiency advantage for boosting NAD+ levels. NR does not cause flushing and does not inhibit sirtuins. It is marketed primarily as a longevity supplement under brand names like Tru Niagen. NR has the most human clinical trial data among the newer NAD+ precursors, though the trials are mostly small and short-term.⁵

Nicotinamide mononucleotide (NMN) is one step closer to NAD+ in the biosynthetic pathway. NMN is converted to NAD+ by NMNAT enzymes. Evidence supports the existence of a dedicated NMN transporter (SLC12A8) in the gut, though the relative importance of direct NMN transport versus extracellular conversion to NR before absorption remains debated. NMN supplements are widely available and often cheaper than NR, though product quality varies significantly. A 2025 analysis found that 87% of tested NR supplements failed to meet label claims, and similar quality concerns apply to NMN products.

The practical distinction for consumers: nicotinic acid and nicotinamide are the traditional forms for preventing deficiency and treating pellagra. NR and NMN are the forms being studied for NAD+ restoration and potential longevity benefits. These are different use cases with different evidence bases, and conflating them is one of the most common errors in consumer supplement marketing.

The cholesterol story: rise and fall

Niacin’s history as a cardiovascular drug is a cautionary tale about treating laboratory values rather than clinical outcomes.

Nicotinic acid at pharmacological doses (1,500-3,000 mg/day) produces impressive lipid panel changes: it raises HDL-C by up to 25%, lowers LDL-C, and reduces triglycerides and lipoprotein(a). Early trials, including the Coronary Drug Project in the 1970s, showed that niacin monotherapy reduced the risk of nonfatal myocardial infarction, and long-term follow-up suggested a mortality benefit. Niacin became a standard component of lipid management, sometimes used alongside statins.

Then came two large, well-designed trials that changed the picture.

The AIM-HIGH trial (2011) randomized 3,414 patients with established cardiovascular disease to extended-release niacin or placebo, on top of statin therapy. Despite improving lipid numbers, niacin did not reduce the composite endpoint of cardiovascular events. The trial was stopped early for futility.⁶

HPS2-THRIVE (2014) was even larger: 25,673 patients with vascular disease randomized to extended-release niacin plus laropiprant (a flush-reducing agent) or placebo, on top of statin therapy. Again, niacin did not reduce major vascular events. Worse, it significantly increased serious adverse events, including new diabetes diagnoses (up by one-third), gastrointestinal problems, infections, and bleeding. Quality-adjusted life-years were significantly worse in the niacin group.⁷

The consensus from these trials is clear: niacin added to statin therapy does not reduce cardiovascular events and causes meaningful harm. As one cardiologist put it, niacin “should be relegated to medical history” for cardiovascular purposes. The lesson extends beyond niacin: improving a biomarker (HDL cholesterol) is not the same as improving a clinical outcome (fewer heart attacks and strokes).

NAD+ precursors and aging: where the evidence stands

The premise is straightforward: NAD+ levels decline approximately 50% between ages 40 and 60. Lower NAD+ means reduced sirtuin activity and impaired DNA repair, while mitochondrial function deteriorates. If supplementing with NAD+ precursors can restore youthful NAD+ levels, the downstream cellular benefits might follow.

Animal data supporting this premise is robust. NR and NMN supplementation in aged mice restores NAD+ levels, improves mitochondrial function, increases insulin sensitivity, and in some models extends lifespan. The animal evidence is the reason the supplement industry has embraced these compounds so enthusiastically.

Human data is less convincing. Multiple trials have confirmed that NR and NMN supplementation reliably raises blood NAD+ levels in humans. That part works. What hasn’t been established is whether those increased NAD+ levels translate into clinical benefits.

A pilot study of NR in older adults with mild cognitive impairment found that NR was safe and raised NAD+ levels but did not significantly improve cognitive function over 10 weeks.⁸ A 2025 systematic review and meta-analysis of NMN and NR effects on skeletal muscle found no significant improvements in muscle mass, strength, or physical performance in older adults.⁹ Individual NMN trials have reported improvements in specific outcomes like skeletal muscle insulin sensitivity in prediabetic women, but the evidence base remains fragmented and preliminary.

The honest assessment: NAD+ precursors raise NAD+ levels in humans. Whether that translates into meaningful health or longevity benefits has not been demonstrated in clinical trials. The biological rationale is strong, the animal data is compelling, and the human data is early-stage and inconclusive. This is the same evidentiary stage that many promising supplement interventions occupy before larger, longer trials either confirm or refute the preliminary findings.

Pellagra and deficiency

Niacin deficiency causes pellagra, characterized by the classic “four Ds”: dermatitis, diarrhea, dementia, and death if untreated. Pellagra was epidemic in the American South in the early 20th century, particularly among populations subsisting primarily on corn, which contains niacin in a bound form (niacytin) that humans cannot absorb without alkaline processing. The discovery that pellagra was a nutritional deficiency rather than an infectious disease, and its subsequent eradication through grain fortification, is one of the major public health achievements of the 20th century.

Today, pellagra is rare in developed countries because of mandatory niacin fortification of flour and cereals. It still occurs in populations with severely restricted diets, heavy alcohol use, or malabsorption conditions. The RDA for niacin is 16 mg NE/day for men and 14 mg NE/day for women (NE = niacin equivalents, accounting for the body’s ability to synthesize niacin from the amino acid tryptophan at a ratio of approximately 60:1).

Safety

The safety profile of niacin depends entirely on which form and what dose.

Nicotinic acid at pharmacological doses (1,000+ mg/day) causes flushing in most users, and extended-release formulations have been associated with hepatotoxicity. The serious adverse events documented in HPS2-THRIVE (increased diabetes, infections, gastrointestinal problems, bleeding, and musculoskeletal complications) make high-dose nicotinic acid a risk that is difficult to justify without a clear clinical indication.

Nicotinamide at standard supplemental doses is well-tolerated. At very high doses, hepatotoxicity has been reported in animal studies, and its inhibition of sirtuins is a theoretical concern for long-term high-dose use.

NR and NMN have shown good safety profiles in human trials to date. NR has been studied at doses up to 1,000 mg/day for up to 12 weeks without serious adverse events. NMN has been similarly well-tolerated in studies lasting up to 24 weeks. Long-term safety data for either compound is limited.

The tolerable upper intake level for niacin (as nicotinic acid or nicotinamide) is set at 35 mg/day for adults, based on the flushing threshold for nicotinic acid. This UL does not apply to NR or NMN, which do not cause flushing and were not considered when the UL was established.

Conclusion

Niacin is a vitamin with three lives. In its classical role as vitamin B3, it prevents pellagra and supports NAD+-dependent energy metabolism. That story is settled. In its pharmacological role as a cholesterol drug, it has been largely discredited by the AIM-HIGH and HPS2-THRIVE trials for use alongside statin therapy. In its newest incarnation as the rationale behind NR and NMN longevity supplements, the biological premise is sound but the clinical proof is missing.

For most people, dietary niacin intake from fortified grains, meat, fish, and legumes is adequate. Supplementing with standard niacin (nicotinic acid or nicotinamide) makes sense for addressing deficiency. Supplementing with NR or NMN for anti-aging purposes is a bet on a hypothesis that hasn’t been confirmed in human clinical trials, backed by strong animal data and plausible biology but not yet by the kind of evidence that would make it a confident recommendation. If you do take NR or NMN, verify product quality through third-party testing, because the supplement market for these compounds has significant quality control problems.

Generate Your Stack. Avoid Conflicts. Optimize Absorption.

Most supplement advice ignores timing, interactions, and dose-response curves. Smart Stack Builder doesn't. Get a personalized daily schedule with interaction flags and dosage guidance, built on the same evidence base as this article.

Build Your Personalized Stack — $9.99

Niacin and NAD+: vitamin B3, from pellagra to longevity supplements